Anti-LRRC15 Antibody Drug Conjugates

This patent discloses antibody-drug conjugates (ADCs) comprising anti-LRRC15 antibodies conjugated to topoisomerase I inhibitor payloads (exatecan) via cleavable peptide-based chemical linkers. LRRC15 (Leucine-Rich Repeat Containing 15) is expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) as well as directly on mesenchymal-derived tumor cells.

The invention describes ADC compositions, drug-to-antibody ratio (DAR) profiles, payload conjugation methods, and formulations demonstrating antitumor activity, linker stability, and pharmacokinetics in preclinical models.

Key Patent Information

• WIPO Publication No.: WO/2026/112472 A1
• PCT Application No.: PCT/US2025/056634
• U.S. Patent Application No.: US 2026/0144884 A1
• Current Status: U.S. Patent Application Allowed (Notice of Allowance issued)
• Priority Date: November 22, 2024
• Publication Date: May 28, 2026
• Assignee: Bristol-Myers Squibb Company
• Inventors: Sayumi Yamazoe, Sonia G. Tanlimco, Lore Florin, Philip M. Vitorino, Qinqin Cheng, Christine H. Tan, Yuntao Zhang, Sunitha Bachawal, Hok Yee Chan, Winse Hong Morishige, Andrew W. Drake, Deanne M. Lathers, Jaimee C. Wong

Recommended citation: Sayumi Yamazoe, Sonia G. Tanlimco, Lore Florin, Philip M. Vitorino, Qinqin Cheng, Christine H. Tan, Yuntao Zhang, Sunitha Bachawal, Hok Yee Chan, Winse Hong Morishige, Andrew W. Drake, Deanne M. Lathers, Jaimee C. Wong. (2026). "Anti-LRRC15 Antibody Drug Conjugates." WIPO Patent Publication No. WO/2026/112472 A1 (U.S. Patent Application No. US 2026/0144884 A1; U.S. Notice of Allowance Issued).
Download Paper